ROI appears to be on track, with four out of five seeing their gen AI investments paying off within three years.

Generative AI is transforming pharma’s slowest lane —regulatory affairs — into a fast track for life-saving treatments. Bringing a new drug to market is one of the most expensive and time-consuming ...